COPENHAGEN (Reuters) – Novo Nordisk (NYSE:) plans to complete its acquisition of Catalent (NYSE:) later this year, its chief financial officer said during the company’s capital markets day on Thursday, adding that Novo’s gross profit is expected to decline next year. coming years.
